These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35749755)

  • 21. Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
    Chaudhary A; Madhavan R; Babji S; Raju R; Syed C; Kumar A; Saravanan P; Sharon Nikitha O; Leander Xavier JV; David Chelladurai JS; Deborah AA; George A; Kang G; Rose W
    Vaccine; 2023 Jul; 41(33):4808-4822. PubMed ID: 37357073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
    Vogel E; Kocher K; Priller A; Cheng CC; Steininger P; Liao BH; Körber N; Willmann A; Irrgang P; Held J; Moosmann C; Schmidt V; Beileke S; Wytopil M; Heringer S; Bauer T; Brockhoff R; Jeske S; Mijocevic H; Christa C; Salmanton-García J; Tinnefeld K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U; Schober K; Tenbusch M
    EBioMedicine; 2022 Nov; 85():104294. PubMed ID: 36206622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
    Tanner R; Starr N; Perez-Garcia CN; Chan G; Dempsey E; Heffernan E; Lynch B; Hannan MM; Joyce E
    Transpl Infect Dis; 2022 Dec; 24(6):e13935. PubMed ID: 35980217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients.
    Busà R; Russelli G; Miele M; Sorrentino MC; Di Bella M; Timoneri F; Di Mento G; Mularoni A; Vitulo P; Conaldi PG; Bulati M
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study.
    Firinu D; Perra A; Campagna M; Littera R; Meloni F; Sedda F; Conti M; Costanzo G; Erbi M; Usai G; Locci C; Carta MG; Cappai R; Orrù G; Del Giacco S; Coghe F; Chessa L
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis.
    Angkasekwinai N; Prawjaeng J; Leelahavarong P; Khuntha S; Pheerapanyawaranun C; Chitpim N; Srinonprasert V; Chokephaibulkit K
    Asian Pac J Allergy Immunol; 2022 Dec; 40(4):321-336. PubMed ID: 36681658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA Vaccination.
    Catry E; Favresse J; Gillot C; Bayart JL; Frérotte D; Dumonceaux M; Evrard P; Mullier F; Douxfils J; Carlier FM; Closset M
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
    Murray SM; Barbanti M; Campbell C; Brown A; Chen L; Dhanapal J; Tseu B; Pervaiz O; Peters L; Springett S; Danby R; Adele S; Phillips E; Malone T; Amini A; Stafford L; Deeks AS; Dunachie S; Klenerman P; Peniket A; Barnes E; Kesavan M
    Br J Haematol; 2022 Aug; 198(4):668-679. PubMed ID: 35655410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort.
    Huang CF; Jang TY; Wu PH; Kuo MC; Yeh ML; Wang CW; Liang PC; Wei YJ; Hsu PY; Huang CI; Hsieh MY; Lin YH; Hsiao HH; Hsu CM; Huang CT; Lee CY; Chen YH; Chen TC; Lin KD; Wang SH; Wang SF; Huang JF; Dai CY; Chuang WL; Yu ML
    Virol J; 2023 Jun; 20(1):112. PubMed ID: 37268999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients.
    Chu C; Schönbrunn A; Fischer D; Liu Y; Hocher JG; Weinerth J; Klemm K; von Baehr V; Krämer BK; Elitok S; Hocher B
    Front Immunol; 2023; 14():1187880. PubMed ID: 37377957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
    Liu Y; Sánchez-Ovando S; Carolan L; Dowson L; Khvorov A; Jessica Hadiprodjo A; Tseng YY; Delahunty C; Khatami A; Macnish M; Dougherty S; Hagenauer M; Riley KE; Jadhav A; Harvey J; Kaiser M; Mathew S; Hodgson D; Leung V; Subbarao K; Cheng AC; Macartney K; Koirala A; Marshall H; Clark J; Blyth CC; Wark P; Kucharski AJ; Sullivan SG; Fox A
    Vaccine; 2023 Nov; 41(48):7192-7200. PubMed ID: 37903679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine.
    Yang J; Ko JH; Baek JY; Hong J; Ha S; Lee B; Huh K; Cho SY; Kang CI; Chung DR; Kim YJ; Kang ES; Peck KR
    Front Immunol; 2021; 12():744206. PubMed ID: 34630425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study.
    Ajlan AA; Ali T; Aleid H; Almeshari K; DeVol E; Alkaff MA; Fajji L; Alali A; Halabi D; Althuwaidi S; Alghamdi S; Ullah A; Alrajhi A; Bzeizi K; Almaghrabi R; Marquez KAH; Elmikkaoui B; Albogumi E; Aldakhil H; Al-Awwami M; Broering DC
    BMC Infect Dis; 2022 Oct; 22(1):786. PubMed ID: 36229772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
    Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
    Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients.
    Natori Y; Martin E; Mattiazzi A; Arosemena L; Ortigosa-Goggins M; Shobana S; Roth D; Kupin WL; Burke GW; Ciancio G; Morsi M; Phancao A; Munagala MR; Butrous H; Manickavel S; Sinha N; Sota K; Pallikkuth S; Bini J; Simkins J; Anjan S; Vianna RM; Guerra G
    Transpl Int; 2023; 36():10938. PubMed ID: 37091963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination.
    Chiang TP; Alejo JL; Mitchell J; Kim JD; Abedon AT; Karaba AH; Thomas L; Levan ML; Garonzik-Wang JM; Avery RK; Pekosz A; Clarke WA; Warren DS; Tobian AAR; Massie AB; Segev DL; Werbel WA
    Am J Transplant; 2022 Sep; 22(9):2254-2260. PubMed ID: 35429211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of mRNA Vaccine Immunogenicity in Solid Organ Transplant Recipients.
    Tsoutsoura P; Xagas E; Roussos S; Hatzakis A; Gourzi P; Boletis IN; Marinaki S
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374279
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital.
    Limpawittayakul P; Sungkasubun P; Chaiwiriyawong W; Supavavej A; Weerasubpong B; Siripaibun J; Phanthunane C; Lamlertthon W; Ungtrakul T; Tawinprai K; Tantiyavarong W; Samdaengpan C
    Hum Vaccin Immunother; 2022 Nov; 18(6):2104058. PubMed ID: 35976687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.